Dr. Erika P. Hamilton on the Shifting Treatment Paradigm in HER2-Positive Breast Cancer
Erika P. Hamilton, MD, discusses the current treatment paradigm, and upcoming treatments, for HER2-positive breast cancer.
Erika P. Hamilton , MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the current treatment paradigm, and upcoming treatments, for HER2-positive breast cancer. She cites the approval of drugs like pertuzumab and T-DM1 over the years as a step in the right direction for treatment of HER2-positive breast cancer, and goes on to say that oncologists have more of an option in treatment now than ever before.
Hamilton says the biggest challenge oncologists face now is figuring out where to place these drugs in the treatment paradigm. She says as T-DM1 and pertuzumab are used more in the neoadjuvant or adjuvant space, the metastatic sequence may be up in the air more.
FDA Grants Clearance for Phase 1 Trial of BL-M17D1 in Solid Tumors
November 11th 2024Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel antibody-drug conjugate BL-M17D1 in patients with advanced or metastatic solid tumors.
Read More
